Activity of commonly used antimicrobial prophylaxis regimens against pathogens causing coronary artery bypass graft and arthroplasty surgical site infections in the United States, 2006-2009

Infection Control and Hospital Epidemiology

Volumn 35, Issue 3, 2014, Pages 231-239

  Berríos Torres, Sandra I ^a   Yi, Sarah H ^a   Bratzler, Dale W ^b   Ma, Allen ^c   Mu, Yi ^a   Zhu, Liping ^a   Jernigan, John A ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c Oklahoma Foundation for Medical Quality   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC PROPHYLAXIS; CORONARY ARTERY BYPASS GRAFT; FEMALE; HIP ARTHROPLASTY; HUMAN; INCIDENCE; KNEE ARTHROPLASTY; MALE; MICROBIOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; SURGICAL WOUND INFECTION; UNITED STATES;

AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CORONARY ARTERY BYPASS; FEMALE; HUMANS; INCIDENCE; MALE; SURGICAL WOUND INFECTION; UNITED STATES;

EID: 84893928585     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/675289     Document Type: Article

References (40)

1. De Frances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National Hospital Discharge Survey. June 30 ed. Hyattsville, MD: National Center for Health Statistics, 2008.
2. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project net (H7CUPnet) website. 2011 Nationwide Inpatient Sample (NIS). Published 2013. http://hcupnet.ahrq.gov/. Accessed June 27, 2013.
3. Abboud CS, Wey SB, Baltar VT. Risk factors for mediastinitis after cardiac surgery. Ann Thorac Surg 2004;77(2):676-683.
4. Sharma M, Fakih MG, Berriel-Cass D, Meisner S, Saravolatz L, Khatib R. Harvest surgical site infection following coronary artery bypass grafting: risk factors, microbiology, and outcomes. Am J Infect Control 2009;37(8):653-657.
5. Urquhart DM, Hanna FS, Brennan SL, et al. Incidence and risk factors for deep surgical site infection after primary total hip arthroplasty: a systematic review. J Arthroplasty 2010;25(8): 1216-1222.
6. Kurtz SM, Ong KL, Lau E, Bozic KJ, Berry D, Parvizi J. Prosthetic joint infection risk after TKA in the medicare population. Clin Orthop Relat Res 2010;468(1):52-56.
7. Risnes I, Abdelnoor M, Almdahl SM, Svennevig JL. Mediastinitis after coronary artery bypass grafting risk factors and long-term survival. Ann Thorac Surg 2010;89(5):1502-1509.
8. Hollenbeak CS, Murphy DM, Koenig S, Woodward RS, Dun-agan WC, Fraser VJ. The clinical and economic impact of deep chest surgical site infections following coronary artery bypass graft surgery. Chest 2000;118(2):397-402.
9. McGarry SA, Engemann JJ, Schmader K, Sexton DJ, Kaye KS. Surgical-site infection due to Staphylococcus aureus among elderly patients: mortality, duration of hospitalization, and cost. Infect Control Hosp Epidemiol 2004;25(6):461-467.
10. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty 2012;27(suppl 8):61.e1-65.e1.
11. Hellmann M, Mehta SD, Bishai DM, Mears SC, Zenilman JM. The estimated magnitude and direct hospital costs of prosthetic joint infections in the United States, 1997 to 2004. J Arthroplasty 2010;25(5):766-771.
12. US Department of Health and Human Services. HHS Action Plan to Prevent Healthcare Associated Infections: Appendix G. http://www.hhs.gov/ash/initiatives/hai/actionplan/. Accessed March 5, 2012.
13. Medical Letter. Antimicrobial prophylaxis for surgery. Treat Guidel Med Lett. 2009;7(82):47-52.
14. Engelman R, Shahian D, Shemin R, et al. The Society of Thoracic Surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice. Ann Thorac Surg 2007; 83(4):1569-1576.
15. American Academy of Orthopaedic Surgeons. Information Statement: Recommendations for the Use of Intravenous Antibiotic Prophylaxis in Primary Total Joint Arthroplasty. Published 2004. http://www6.aaos.org/news/PDFopen/PDFopen.cfm?page_urlphttp://www.aaos.org/about/papers/advistmt/1027.asp. Accessed February 8, 2012.
16. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013;70(3):195-283.
17. Bratzler DW, Hunt DR. The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. Clin Infect Dis 2006; 43(3):322-330.
18. Malpiedi PJ, Peterson KD, Soe MM, et al. 2011 National and State Healthcare-Associated Infection Standardized Infection Ratio Report. Published 2013. http://www.cdc.gov/hai/pdfs/SIR/SIR-Report_02_07_2013.pdf. Accessed June 13, 2013.
19. Anderson DJ, Arduino JM, Reed SD, et al. Variation in the type and frequency of postoperative invasive Staphylococcus aureus infections according to type of surgical procedure. Infect Control Hosp Epidemiol 2010;31(7):701-709.
20. Centers for Disease Control and Prevention. National Healthcare Safety Network: Surgical Site Infection (SSI) Event. http://www.cdc.gov/nhsn/PDFs/pscManual/9pscSSIcurrent.pdf. Accessed February 8, 2012.
21. QualityNet. Specifications Manual for National Hospital Inpatient Quality Measures. Version 1.04a-3.0c. http://www.qualitynet.org/dcs/ContentServer?cpPage&pagenamepQnetPublic%2FPage%2FQnetTier4&cidp1228695698425. Accessed June 15, 2012.
22. Mu Y, Edwards JR, Horan TC, Berrios-Torres SI, Fridkin SK. Improving risk-adjusted measures of surgical site infection for the national healthcare safety network. Infect Control Hosp Epidemiol 2011;32(10):970-986.
23. Bratzler DW, Houck PM; Surgical Infection Prevention Guidelines Writers Group. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004;38(12):1706-1715.
24. Mandell GL, Bennet JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone, 2005.
25. Anderson DJ, Kaye KS, Chen LF, et al. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study. PLoS ONE 2009;4(12):e8305.
26. Kurtz SM, Ong KL, Schmier J, et al. Future clinical and economic impact of revision total hip and knee arthroplasty. J Bone Joint Surg Am 2007;89(suppl 3):144-151.
27. Miller LG, McKinnell JA, Vollmer ME, Spellberg B. Impact of methicillin-resistant Staphylococcus aureus prevalence among S. aureus isolates on surgical site infection risk after coronary artery bypass surgery. Infect Control Hosp Epidemiol 2011;32(4):342-350.
28. Chambers D, Worthy G, Myers L, et al. Glycopeptide vs. non-glycopeptide antibiotics for prophylaxis of surgical site infections: a systematic review. Surg Infect (Larchmt) 2010;11(5):455-462.
29. Sewick A, Makani A, Wu C, O'Donnell J, Baldwin KD, Lee GC. Does dual antibiotic prophylaxis better prevent surgical site infections in total joint arthroplasty? Clin Orthop Relat Res 2012; 470(10):2702-2707.
30. Crawford T, Rodvold KA, Solomkin JS. Vancomycin for surgical prophylaxis? Clin Infect Dis 2012;54(10):1474-1479.
31. Bolon MK, Morlote M, Weber SG, Koplan B, Carmeli Y, Wright SB. Glycopeptides are no more effective than b-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. Clin Infect Dis 2004;38(10):1357-1363.
32. Bratzler DW, Houck PM, Richards C, et al. Use of antimicrobial prophylaxis for major surgery-baseline results from the National Surgical Infection Prevention Project. Arch Surg 2005; 140(2):174-182.
33. Rubin ZA, Edwards JR, Horan TC, Jernigan JA. Staphylococcal surgical site infection following coronary artery bypass and joint replacement surgery: National Nosocomial Infections Surveillance System, 1994-2003. In: Program and Abstracts of the Society for Healthcare Epidemiology of America's 15th Annual Scientific Meeting. Arlington, VA: Society for Healthcare Epidemiology of America, 2005. Abstract 42.
34. Finkelstein R, Rabino G, Mashiah T, et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 2002;123(2):326-332.
35. Kitzes-Cohen R, Farin D, Piva G, et al. Pharmacokinetics of vancomycin administered as prophylaxis before cardiac surgery. Ther Drug Monit 2000;22(6):661-667.
36. Martin C, Alaya M, Mallet MN, et al. Penetration of vancomycin into mediastinal and cardiac tissues in humans. Antimicrob Agents Chemother 1994;38(2):396-399.
37. Manian FA, Meyer PL, Setzer J, Senkel D. Surgical site infections associated with methicillin-resistant Staphylococcus aureus: do postoperative factors play a role? Clin Infect Dis 2003;36(7):863-868.
38. Diekema D, Johannsson B, Herwaldt L, et al. Current practice in Staphylococcus aureus screening and decolonization. Infect Control Hosp Epidemiol 2011;32(10):1042-1044.
39. Darouiche RO, Wall MJ Jr, Itani KM, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med 2010;362(1):18-26.
40. Lucero CA, Hageman J, Zell ER, et al. Evaluating the potential public health impact of a Staphylococcus aureus vaccine through use of population-based surveillance for invasive methicillin-resistant S. aureus disease in the United States. Vaccine 2009; 27(37):5061-5068.